Migraine

Migraine Treatment | Ketamine for Migraine

Migraine is more than a severe headache. It is a neurological disorder that can cause intense head pain, nausea, sensory sensitivity, visual disturbances, and other symptoms that may interfere significantly with work, sleep, relationships, and everyday activities. For some adults, migraine attacks remain frequent or disabling despite appropriate preventive medications, acute treatments, and specialist care. When established options have not provided adequate relief, migraine ketamine treatment may become one consideration within a broader treatment plan.

Allay Health & Wellness offers migraine ketamine treatment in Palm Beach Gardens, Florida, as an off label clinical service for appropriately evaluated adults with chronic or refractory migraine presentations. IV ketamine is not FDA approved for migraine or any pain condition, and individual outcomes cannot be predicted or guaranteed. This page explains migraine from a clinical perspective, established treatment approaches, where migraine ketamine treatment may fit in the treatment sequence, what current research supports, potential risks and limitations, and the factors considered when determining candidacy.

What Migraine Is at a Neurobiological Level

Migraine is a complex neurological disorder characterized by recurrent attacks of moderate to severe headache, typically unilateral and throbbing in quality, often accompanied by nausea, vomiting, and sensitivity to light and sound. Approximately one third of people with migraine also experience aura, which is a neurological phenomenon involving visual disturbances, sensory changes, or speech disruption preceding the headache phase. The National Institute of Neurological Disorders and Stroke identifies migraine as one of the most common neurological disorders in the United States, affecting a substantial proportion of adults with disproportionate impact on women and people of working age.

The pathophysiology of migraine involves cortical spreading depression, trigeminal nerve activation, neurogenic inflammation, and central sensitization. This last feature is particularly relevant to the ketamine rationale. Central sensitization during migraine attacks involves NMDA receptor activation in the trigeminal pain pathway, and repeated or inadequately treated migraine attacks can drive progressive sensitization in which the attack threshold decreases and pain becomes increasingly centralized over time. In chronic migraine, defined as headache occurring on fifteen or more days per month for at least three months with migraine features on at least eight of those days, central sensitization is a prominent feature of the clinical picture.

Types of Migraine Evaluated for Ketamine Treatment

Migraine can present differently from one patient to another, and not every presentation has the same relevance to migraine ketamine treatment. At Allay Health & Wellness, evaluation focuses on symptom severity, attack frequency, disability, previous treatment response, and whether established migraine therapies have provided adequate relief.

1. Chronic Migraine: Patients may experience frequent migraine symptoms that continue to interfere with daily functioning despite appropriate preventive treatment. When established preventive medications have been tried at adequate doses and durations without sufficient improvement, additional treatment options may be considered through an individualized clinical evaluation.
2. Status Migrainosus: Status migrainosus is a debilitating migraine attack lasting longer than 72 hours and may require urgent or hospital based medical management. Active status migrainosus is not treated as a routine outpatient infusion appointment. However, patients with recurrent prolonged or difficult to control attacks may discuss appropriate outpatient evaluation after urgent medical needs have been addressed.
3. Refractory Chronic Migraine: Some patients continue to experience disabling migraines despite multiple preventive strategies, which may include CGRP targeted treatments and other established therapies. For appropriately evaluated adults with persistent symptoms, migraine ketamine treatment may be discussed as an off label option while recognizing that evidence remains limited and individual outcomes cannot be guaranteed.

These presentations also fit within Allay Health & Wellness’s broader approach to chronic pain management. Because persistent migraine can occur alongside depression or anxiety, significant psychiatric symptoms may also warrant appropriate mental health evaluation as part of a coordinated care plan.

First Line Treatments for Migraine

Migraine ketamine treatment is not a starting point. The migraine treatment landscape has become substantially richer in recent years, and most patients with migraine have not exhausted the available options before arriving at the off label ketamine conversation. Acute treatments include triptans, gepants including ubrogepant and rimegepant, ditans including lasmiditan, and NSAIDs. For prolonged or severe attacks, dihydroergotamine and IV medications including prochlorperazine, ketorolac, and magnesium are used in clinical settings.

Preventive treatments include topiramate, valproate, propranolol, metoprolol, amitriptyline, and venlafaxine as first generation options, and the CGRP pathway treatments, specifically erenumab, fremanezumab, galcanezumab, and eptinezumab as monoclonal antibodies, and rimegepant and atogepant as oral gepants with preventive indication. OnabotulinumtoxinA is FDA approved specifically for chronic migraine prevention. The American Headache Society and the American Academy of Neurology maintain guidelines on migraine treatment worth reviewing with any headache specialist before considering off label options.

Migraine ketamine treatment is for patients who have genuinely worked through this landscape, not patients who have tried one or two medications and moved on. A patient who has been through two or more preventive medications without adequate relief, who has optimized acute therapy, and who is still experiencing significant disability from migraine frequency is the appropriate clinical candidate.

Why Ketamine Is Relevant to Migraine Biology

Migraine ketamine treatment has a meaningful mechanistic rationale, and it rests on two specific features of migraine neurobiology. The first involves NMDA receptors and central sensitization. As migraine attacks recur and sensitization develops, NMDA receptor mediated processes may contribute to cutaneous allodynia, expansion of pain sensitivity, and migraine chronification. Ketamine acts as an NMDA receptor antagonist, which provides a biological rationale for studying whether it can influence sensitized pain processing rather than simply addressing symptoms during an individual attack.

The second involves cortical excitability. Cortical spreading depression, a wave of neuronal and glial depolarization associated with migraine aura, involves glutamatergic signaling. Ketamine’s effects on glutamate pathways have therefore generated interest in whether it could influence processes relevant to migraine susceptibility, although this potential mechanism remains less established than its relationship with central sensitization. These mechanisms also overlap with the way ketamine affects anxiety related neural pathways, particularly through glutamate and NMDA receptor modulation. From a pain perspective, the same pharmacological activity helps explain why ketamine for chronic pain has been investigated in conditions involving central sensitization and altered pain processing.

What the Evidence Shows for Migraine Ketamine Treatment

The evidence base for migraine ketamine treatment is more developed than for some other chronic pain conditions and more specific in its clinical application than for back pain or fibromyalgia. IV ketamine has been studied most extensively in the context of status migrainosus and refractory migraine. A retrospective review published in Headache examined patients with refractory migraine and status migrainosus treated with IV ketamine in an inpatient headache unit setting. Patients showed significant reductions in pain scores, and the authors noted that migraine ketamine treatment was effective in a substantial proportion of patients who had failed standard acute treatments including triptans, DHE, and IV neuroleptics.

A subsequent prospective study in a headache specialty inpatient setting found that low dose IV ketamine infusions reduced headache severity in patients with intractable migraine who had not responded to conventional treatments. Functional status scores improved alongside pain reduction, suggesting the benefit extended beyond simple analgesic effect. The evidence for outpatient IV ketamine in chronic migraine prevention is less developed than the inpatient refractory evidence. Most published data comes from case series and retrospective analyses. The emerging picture suggests that migraine ketamine treatment is most clearly supported for refractory and intractable presentations rather than as a general preventive strategy, and patients considering it should understand this distinction.

The Off Label Reality

Migraine ketamine treatment is an off label use. The FDA has not approved IV ketamine for migraine or for any pain condition. Its only approved indication is as a general anesthetic. Spravato (esketamine) is not approved for migraine. Its approved indications are treatment resistant depression in adults and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Spravato is not used at Allay Health and Wellness for migraine or any pain condition.

Off label prescribing is legal and standard across medicine, and a number of medications used routinely for migraine prevention, including several antidepressants and anticonvulsants, were adopted off label before formal migraine specific indications existed. Migraine ketamine treatment is in a comparable position: the evidence is clinical and mechanistic, and regulatory status has not yet caught up with specialized use.

Migraine, Mood, and the Shared Neurobiology

Chronic migraine and major depressive disorder frequently occur together, and their relationship can meaningfully influence the overall clinical picture. Both conditions involve complex changes in pain processing, mood regulation, sleep, and neurotransmitter systems, including serotonergic and glutamatergic pathways. Persistent migraine can contribute to depressive symptoms through disability, disrupted sleep, and reduced quality of life, while depression may intensify the burden associated with chronic migraine.

For patients experiencing significant depression alongside chronic migraine, each condition deserves appropriate evaluation rather than assuming that improvement in one will resolve the other. When depression is part of the presentation, ketamine therapy for depression may become a separate component of the clinical discussion based on diagnosis, previous treatment response, and individual eligibility. Daniel Cartledge, M.D., our clinical consultant, is double board certified in pain management and physical medicine and rehabilitation, bringing relevant experience to patients whose pain and psychiatric concerns overlap. Patients can also review the backgrounds and credentials of the broader Allay Health & Wellness clinical team before deciding whether to schedule an evaluation.

What Treatment Involves at Allay

Every patient considering migraine ketamine treatment at Allay Health & Wellness begins with an individualized clinical evaluation. Our process reviews your migraine history, previous treatments, overall health, and current care before determining whether off label IV ketamine may be appropriate.

• Evaluation: Intake covers your migraine history, preventive and acute medications previously tried with doses and durations, current specialist care, cardiovascular health, substance use history, and co occurring depression or anxiety. No referral is required. Bring your available clinical records to support a thorough evaluation.
• The Sessions: IV ketamine is administered slowly through an intravenous line in a private, monitored room. A licensed clinician remains present and monitors vital signs throughout treatment. Session duration and treatment frequency depend on the protocol and individual clinical response. For migraine ketamine treatment, pain protocols may differ from psychiatric protocols. During consultation, we also discuss how many ketamine therapy sessions may be needed and why the treatment schedule can vary between patients.
• After Sessions: You may not drive after an infusion. A responsible adult must arrange transportation home, and you should follow the individualized post treatment instructions provided by your clinical team.

Who May Be a Candidate

A clinical evaluation is required before Allay Health & Wellness makes any recommendation for migraine ketamine treatment. Potential candidates may include adults with chronic or refractory migraine who have experienced inadequate improvement despite established preventive and acute treatments. Previous care with a neurologist or headache specialist, medication history, CGRP targeted treatments when appropriate, cardiovascular health, psychiatric history, and current migraine management are reviewed during evaluation.

Medication overuse headache should also be identified and appropriately addressed because frequent use of certain acute medications can contribute to migraine chronification and complicate treatment response. Allay Health & Wellness treats adults age 18 and older exclusively. Because ketamine is a federally regulated Schedule III controlled substance, substance use history is reviewed individually as part of the safety assessment rather than treated as an automatic exclusion. Patients who want to understand the evaluation process can review common questions in our ketamine therapy FAQ, including safety and treatment expectations. Ultimately, medical history, current medications, previous treatment response, and potential contraindications determine who may be eligible for ketamine therapy.

Risks and Side Effects of Migraine Ketamine Treatment

Every patient evaluated for migraine ketamine treatment receives a clear explanation of potential risks, side effects, and treatment limitations before anything is scheduled. Ketamine can cause temporary dissociation, including changes in perception, awareness, time, or sense of self, and clinical staff monitor these effects throughout treatment. Sedation can also occur, so patients may not drive after an infusion and must arrange transportation home.

Temporary increases in blood pressure and heart rate can occur and are monitored before, during, and after every session. Nausea may be particularly relevant for migraine patients who already experience nausea during attacks, and clinicians may consider anti nausea medication based on individual history and clinical judgment. Some patients also experience vivid perceptual or emotional changes during treatment.

Ketamine is a federally regulated Schedule III controlled substance, making the question of whether ketamine can be addictive an important part of informed treatment discussions. Dependency and misuse risks are reviewed during evaluation. No outcome from migraine ketamine treatment is guaranteed, and individual responses vary considerably.

FAQs about Migraine Ketamine Treatment

1. Is ketamine FDA-approved for migraine?
   No. Migraine ketamine treatment is an off-label use. The FDA has not approved IV ketamine for migraine or any pain condition. Research on ketamine for refractory migraine remains limited, with much of the available evidence coming from observational, retrospective, and specialized clinical settings rather than large randomized controlled trials.
2. I have tried triptans and they sometimes work. Is ketamine appropriate?
   Not necessarily. Migraine ketamine treatment is generally considered only after established treatment options have provided inadequate relief. If triptans remain partially effective, your clinician may recommend optimizing acute treatment or considering appropriate preventive options before discussing off-label ketamine. Individual treatment decisions require a clinical evaluation.
3. What is status migrainosus, and is it treated at Allay?
   Status migrainosus generally refers to a debilitating migraine attack lasting longer than 72 hours. Management may require urgent or specialized medical care depending on severity and associated symptoms. Patients with recurrent prolonged or treatment-resistant migraines may discuss outpatient evaluation at Allay Health & Wellness, but an active medical emergency requires appropriate emergency care rather than a scheduled ketamine consultation.
4. Does insurance cover migraine ketamine treatment?
   Off-label IV ketamine is generally not covered by most insurance plans. Allay Health & Wellness accepts Medicare, Cigna, UnitedHealthcare, and Aetna for eligible services. Our team verifies available benefits and provides anticipated cost information before treatment is scheduled. Coverage varies by plan and is never guaranteed.
5. Do I need a referral from a neurologist?
   No formal referral is required. However, coordination with a neurologist or headache specialist can be important when managing refractory migraine. During evaluation, we review your current providers, previous migraine treatments, and available clinical records. If additional specialist assessment is appropriate, referral options can be discussed.

Schedule a Consultation for Migraine Ketamine Treatment

If chronic or refractory migraine has not responded adequately to established treatments, Allay Health & Wellness is available to discuss whether migraine ketamine treatment may have a place in your care. Our clinical team reviews your migraine history, previous treatments, current medications, overall health, and specialist involvement before making any recommendation. We also explain the off label status of IV ketamine, current evidence, potential risks, and treatment limitations so you can make an informed decision.

Patients who want to explore the evidence before proceeding can review the peer reviewed research that informs our clinical approach and learn more about the experience and credentials of the Allay Health & Wellness clinical team. Allay Health & Wellness treats adults aged 18 and older exclusively.

Address: 11000 Prosperity Farms Rd, Suite 101, Palm Beach Gardens, FL 33410
Email: [email protected]
Phone: (561) 421-6444

Contact Allay Health & Wellness to schedule a consultation and discuss whether further evaluation for migraine ketamine treatment may be appropriate.

Medical Disclaimer: This content is educational only and not a substitute for professional medical advice. IV ketamine for migraine is an off-label use, not FDA-approved for migraine or any pain condition. Spravato is not approved for migraine. Standard preventive and acute migraine treatments should be tried before off-label options. Evidence for ketamine in migraine is promising but primarily from inpatient and retrospective data. Individual outcomes vary and are never guaranteed. Allay treats adults 18 and older.

Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness